neuromuscular disease: Any disease that impairs the functioning of the muscles, either directly, being pathologies of the voluntary muscle, or indirectly, being pathologies of nerves or neuromuscular junctions
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
137 |
4. Check minimum number of eventsNone |
137 |
5. Include endpointsNone |
137 |
6. Filter based on genotype QC (FinnGen only) |
128 |
Control definitions (FinnGen only)
- Control exclude
- G6_MYONEU
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Other and unspecified myoneural disorders
based on the number of shared cases.
Similar with more cases:
- Diseases of the myoneural junction and muscle
- Neurological diseases
- Neurological diseases, wide definition
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1011 | 506 | 489 |
| Only index persons | 841 | 448 | 393 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 61.18 | 58.65 | 63.71 |
| Only index persons | 59.26 | 56.81 | 62.04 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 128 | 76 | 52 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.02 |
| Median age at first event (years) | 54.37 | 48.93 | 62.33 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 137
- Matched controls
- 1370
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G70.9
ICD-10 Finland
Myoneural disorder, unspecified
+∞
132.8
105
*
N07AA02
ATC
pyridostigmine; systemic
995.0
111.9
95
*
G70.0
ICD-10 Finland
Myasthenia gravis
+∞
100.9
84
*
108
Kela drug reimbursment
Myasthenia gravis
+∞
98.0
82
*
L04AX01
ATC
azathioprine; systemic
45.7
78.7
50
17
G70.8
ICD-10 Finland
Other specified myoneural disorders
+∞
37.2
34
*
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
8.8
25.7
38
57
N07AA03
ATC
distigmine; systemic
151.5
24.5
25
*
A12BA01
ATC
potassium chloride; oral
18.6
20.7
32
22
G70
ICD-10 Finland
Myasthenia gravis and other myoneural disorders
+∞
20.3
19
*
R03CA02
ATC
ephedrine; oral
123.0
20.2
21
*
H02.4
ICD-10 Finland
Ptosis of eyelid
17.9
19.2
30
21
G72.9
ICD-10 Finland
Myopathy, unspecified
+∞
17.0
16
*
3580A
ICD-9 Finland
Myoneural disorders, Myasthenia gravis
+∞
15.9
15
*
N99
ICPC
Neurological disease other
179.7
15.8
16
*
H02AB07
ATC
prednisone; oral
5.0
13.8
36
92
GEC24
NOMESCO Finland
Thoracoscopic thymectomy
+∞
12.7
12
*
H53.2
ICD-10 Finland
Diplopia
12.2
11.8
21
20
5872
FHL
Thymic exploration or thymectomy
+∞
11.6
11
*
G70.28
ICD-10 Finland
Other congenital and developmental myasthenia
+∞
10.5
10
*
R13
ICD-10 Finland
Dysphagia
5.3
10.4
23
50
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.2
10.4
68
320
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.9
10.3
37
119
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
4.6
9.8
26
66
G70.20
ICD-10 Finland
Congenital and developmental myasthenia
+∞
9.5
9
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.0
8.9
81
448
ZX120
NOMESCO Finland
Intravenous
4.0
8.8
28
82
R4130
NOMESCO Finland
Speech therapy
11.9
8.5
15
14
73300
ICD-8 Finland
Other diseases of muscle, tendon and fascia, Myasthenia gravis
+∞
8.4
8
*
3589X
ICD-9 Finland
Myoneural disorders, unspecified
+∞
7.4
7
*
GEC26
NOMESCO Finland
Mediastinoscopic thymectomy
+∞
7.4
7
*
N29
ICPC
Neurological sympt/complt other
21.4
7.2
10
5
R03DA04
ATC
theophylline; systemic, rectal
7.7
7.2
16
23
H02AB06
ATC
prednisolone; systemic
2.7
7.2
82
493
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
4.6
7.1
18
44
WX892
NOMESCO Finland
Monitored bed care
4.6
7.1
18
44
L28
ICPC
Limited function/disability (L)
3.0
6.8
35
139
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.4
6.7
27
92
AA1AD
NOMESCO Finland
CT of head and brain
2.7
6.5
47
224
G72.8
ICD-10 Finland
Other specified myopathies
+∞
6.3
6
*
2AB04, ,
NOMESCO Finland
+∞
6.3
6
*
NJ3CG
NOMESCO Finland
Extensive MRI examination of extremities with median high magnet
+∞
6.3
6
*
GEC23
NOMESCO Finland
Transsternal thymectomy
+∞
6.3
6
*
G73.1*C80.99
ICD-10 Finland
Eaton-Lambert syndrome
+∞
6.3
6
*
G70.1
ICD-10 Finland
Toxic myoneural disorders
+∞
6.3
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
31
9
43.92
25.59
1.2
1.2
30.40
—
nmol/l
—
14
0
93
539
3.26
9.71
7.9
6.7
1.21
1.22
mmol/l
0.14
81
458
33
114
3.50
8.13
11.3
6.3
0.99
1.76
mmol/l
0.63
28
91
100
652
2.98
7.62
16.1
10.0
3.95
3.94
e9/l
0.01
93
573
83
492
2.74
7.61
8.1
5.4
1.21
1.22
mmol/l
0.13
78
455
19
54
3.92
6.13
2.1
1.5
—
—
—
0
0
22
71
3.50
5.93
1.9
1.4
—
—
—
0
0
5
0
+∞
5.24
1.0
0.0
—
—
—
0
0
73
466
2.21
4.95
2.4
2.3
76.38
77.39
nmol/l
0.10
67
417
67
414
2.21
4.92
2.6
2.0
99.15
95.44
pmol/l
0.18
33
211
35
168
2.46
4.60
2.6
1.9
29.40
28.75
s
0.26
35
163
8
8
10.52
4.58
1.5
1.4
—
—
—
0
0
8
8
10.52
4.58
2.5
2.5
—
—
—
0
0
19
68
3.08
4.33
10.0
3.8
24.04
25.26
mmol/l
0.93
19
68
12
28
4.59
3.92
1.3
1.0
—
—
—
0
0
28
130
2.45
3.91
2.8
6.7
1.07
1.03
mmol/l
0.24
28
117
9
15
6.34
3.88
1.1
1.1
—
—
—
0
0
111
886
2.33
3.77
10.0
7.4
80.28
79.38
u/l
0.05
104
828
44
252
2.10
3.74
2.0
1.8
1.09
1.32
mg/l
0.29
34
195
8
12
7.00
3.73
1.1
1.0
—
—
—
0
0
22
93
2.63
3.71
9.3
5.0
1.27
1.20
mmol/l
0.17
22
87
50
306
2.00
3.52
3.5
2.9
1236.35
910.08
ng/l
0.39
39
252
107
853
2.16
3.47
6.7
4.1
14.37
11.46
mm/h
0.88
101
787
61
403
1.93
3.42
5.6
2.8
—
—
—
0
0
8
14
5.99
3.39
1.0
1.1
—
—
—
0
0
33
177
2.14
3.28
2.2
1.7
—
—
—
0
0
73
518
1.88
3.24
19.6
12.3
1.46
1.24
inr
0.48
20
158
16
62
2.79
3.17
12.3
6.9
94.88
94.45
%
0.18
16
62
21
96
2.40
3.02
2.8
2.1
4.29
4.50
ug/l
0.06
15
86
5
5
10.31
3.00
1.0
1.4
—
—
—
0
0
12
38
3.36
2.94
3.2
1.8
—
—
—
0
0
76
561
1.80
2.85
5.9
3.5
0.00
0.00
estimate
-0.00
20
126
106
868
1.98
2.83
4.6
3.9
15.52
14.74
pmol/l
1.57
100
787
5
6
8.59
2.77
2.0
2.7
—
—
—
0
0
19
88
2.35
2.66
1.4
2.6
65.64
67.46
g/l
0.38
19
82
75
561
1.74
2.61
8.3
4.9
0.00
0.00
estimate
-0.00
20
117
5
7
7.36
2.57
1.8
1.1
14.20
13.57
u/l
—
5
7
24
127
2.08
2.45
2.5
1.6
—
—
—
0
0
9
27
3.49
2.44
1.1
1.3
—
—
—
0
0
75
568
1.71
2.44
6.0
3.5
0.00
0.00
estimate
-0.00
17
108
47
314
1.76
2.39
5.4
2.9
0.37
0.47
e6/l
0.16
42
238
5
8
6.43
2.39
1.2
1.0
—
—
—
0
0
78
600
1.70
2.37
6.2
6.4
11.38
10.94
umol/l
0.19
72
565
24
129
2.04
2.35
2.5
1.6
—
—
—
0
0
13
55
2.51
2.20
1.6
1.4
—
—
—
0
0
24
133
1.98
2.17
10.1
5.9
104.63
104.42
mmol/l
0.05
24
133
11
43
2.69
2.13
2.8
1.5
0.22
0.25
g/l
0.36
11
43
95
784
1.69
2.10
3.5
3.0
48.57
45.56
u/l
0.12
88
737
7
20
3.63
2.08
6.9
3.6
63.00
63.30
%
—
7
20
9
32
2.94
2.04
1.4
1.4
—
—
—
0
0
121
1078
2.05
1.97
22.0
12.4
86.80
82.30
ml/min/173m2
1.77
104
889
53
383
1.63
1.96
2.7
3.4
2.36
2.35
mmol/l
0.23
46
345
9
34
2.76
1.90
1.3
1.8
—
—
—
0
0
6
17
3.64
1.86
1.0
1.1
—
—
—
0
0
5
12
4.28
1.84
3.2
1.8
15.58
14.96
ug/l
—
5
12
125
1136
2.15
1.78
26.6
13.1
17.29
22.22
mg/l
1.69
110
878
58
437
1.57
1.77
4.4
3.8
884.52
33.97
ng/l
0.49
42
301
43
302
1.62
1.76
6.3
3.6
0.00
0.00
estimate
-0.00
17
111
14
69
2.15
1.71
3.5
2.7
83.57
98.05
ng/l
0.21
14
59
8
31
2.68
1.69
1.1
1.2
—
—
—
0
0
8
31
2.68
1.69
1.1
1.2
—
—
—
0
0
16
84
2.02
1.68
4.1
7.7
7.00
8.62
mmol/l
0.57
16
78
7
25
2.89
1.67
1.7
1.4
—
—
—
0
0
8
32
2.59
1.62
1.6
1.4
0.00
0.00
g/l
—
8
32
8
32
2.59
1.62
1.6
1.4
0.00
0.00
g/l
—
8
32
6
20
3.09
1.60
1.5
1.1
—
—
—
0
0
29
189
1.68
1.57
2.0
1.7
1199.95
1234.46
nmol/l
0.09
22
145
8
33
2.51
1.56
1.6
1.4
0.00
0.00
g/l
—
8
33
7
28
2.58
1.47
1.4
1.4
—
—
—
0
0
7
28
2.58
1.47
1.4
1.4
—
—
—
0
0
5
16
3.20
1.45
1.4
1.2
—
—
nmol/l
—
0
0
6
23
2.68
1.38
12.2
2.0
26.07
24.34
mmol/l
—
6
23
9
43
2.17
1.33
1.6
1.3
—
—
—
0
0
26
173
1.62
1.30
5.8
2.8
2.94
2.66
e6/l
0.07
16
86
21
133
1.68
1.26
4.3
4.8
30.06
32.59
%
0.73
16
86
8
37
2.23
1.23
1.4
2.0
—
—
—
0
0
8
38
2.17
1.20
1.4
1.1
—
—
—
0
0
27
186
1.56
1.18
2.3
2.5
11.68
13.67
umol/l
0.61
27
173
5
20
2.55
1.16
1.4
1.2
—
—
—
0
0
5
20
2.55
1.16
4.0
3.1
2.06
3.51
nmol/l
—
5
20
55
443
1.40
1.10
6.6
3.6
—
—
—
0
0
35
261
1.46
1.06
1.9
1.6
20.30
21.83
nmol/l
0.29
26
221
12
68
1.84
1.04
1.5
1.2
23.19
125.54
u/ml
2.75
12
62
7
35
2.05
1.01
1.0
1.1
—
—
—
0
0
9
51
1.82
0.96
1.1
1.3
—
—
—
0
0
35
267
1.42
0.94
3.3
2.3
—
—
—
0
0
131
1259
1.92
0.87
40.2
19.8
39.47
40.07
%
0.45
126
1194
6
31
1.98
0.85
1.2
2.0
—
—
—
0
0
27
202
1.42
0.81
1.1
1.3
1.50
6.09
u/ml
—
6
83
7
119
0.57
0.71
1.3
1.8
—
—
—
0
0
25
190
1.39
0.69
5.3
2.6
1.62
1.14
e6/l
0.28
16
103
39
321
1.30
0.65
1.5
1.6
1.48
1.39
mmol/l
0.23
32
269
32
256
1.33
0.65
1.4
1.2
0.62
0.75
u/ml
—
9
78
112
1067
1.27
0.46
5.8
5.4
40.44
39.62
mmol/mol
0.37
106
1000
8
56
1.45
0.43
1.3
1.5
—
—
—
0
0
5
31
1.64
0.43
1.6
1.6
—
—
—
0
0
0
15
0.00
0.41
0.0
1.2
—
2.41
—
0
8
18
142
1.31
0.41
17.0
7.3
—
—
—
0
0
0
18
0.00
0.40
0.0
1.0
—
—
—
0
0
77
713
1.18
0.40
3.5
3.2
—
—
—
0
0
5
36
1.40
0.38
1.8
1.5
—
—
—
0
0
14
108
1.33
0.37
3.6
3.4
—
—
—
0
0
23
193
1.23
0.33
2.3
2.9
0.69
0.77
ug/l
0.27
15
124
58
532
1.16
0.32
5.1
2.5
—
—
—
0
0
7
55
1.29
0.30
6.0
2.8
0.87
1.16
%
—
7
55
114
1107
1.18
0.25
4.7
4.6
6.02
5.90
mmol/l
0.49
108
1015
16
188
0.83
0.23
1.6
1.3
—
—
—
0
0
5
41
1.23
0.22
1.6
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
29
261
1.14
0.20
3.1
4.6
24.36
21.68
%
0.35
14
132
14
118
1.21
0.20
1.6
1.7
—
—
—
0
0
7
58
1.22
0.18
1.3
2.6
26.71
40.68
u/l
—
7
51
37
341
1.12
0.18
3.6
3.7
8.90
7.15
mg/mmol
0.17
23
216
8
70
1.15
0.16
1.3
1.6
—
—
—
0
0
101
987
1.09
0.12
33.0
16.2
14.90
14.86
%
0.02
101
971
107
1090
0.92
0.11
4.0
4.1
1.36
1.28
mmol/l
0.55
99
1007
5
60
0.83
0.08
1.0
1.0
—
—
—
0
0
22
205
1.09
0.08
2.0
1.5
—
—
—
0
0
112
1134
0.93
0.07
4.5
4.5
4.59
4.66
mmol/l
0.35
107
1062
14
129
1.09
0.06
1.6
1.8
—
—
—
0
0
116
1151
1.05
0.03
4.9
5.0
2.75
2.75
mmol/l
0.00
110
1067
112
1127
0.97
0.01
4.5
4.5
1.43
1.49
mmol/l
0.68
105
1045
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.2
—
13.63
—
0
9
0
5
0.00
-0.00
0.0
1.0
—
16.22
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
96.00
—
0
5
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
7
0.00
-0.00
0.0
5.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint G6_MYONEUOTHUNS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_MYONEUOTHUNS | 2.125 [1.59, 2.84] | < 0.001 |
| Birth year | 0.992 [0.98, 1.0] | 0.074 |
During the follow-up period (1.1.1998 — 31.12.2019), 123 out of 407 females with G6_MYONEUOTHUNS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_MYONEUOTHUNS | 2.046 [1.58, 2.65] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.004 |
During the follow-up period (1.1.1998 — 31.12.2019), 166 out of 388 males with G6_MYONEUOTHUNS died.
Mortality risk
Mortality risk for people of age
years, who have G6_MYONEUOTHUNS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.187% | 0.44% |
| 5 | 1.036% | 2.468% |
| 10 | 2.73% | 5.883% |
| 15 | 5.304% | 10.882% |
| 20 | 9.42% | 18.602% |
Relationships between endpoints
↥Index endpoint: G6_MYONEUOTHUNS – Other and unspecified myoneural disorders
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data